Literature DB >> 11409481

Natural history of endometrial hyperplasia. Study of 77 patients.

T Tabata1, T Yamawaki, T Yabana, M Ida, K Nishimura, Y Nose.   

Abstract

Seventy-seven patients with endometrial hyperplasia, 48 with simple hyperplasia without atypia (SH), 17 with complex hyperplasia without atypia (CH), one with simple hyperplasia with atypia (SHA), and 11 with complex hyperplasia with atypia (CHA) were prospectively followed-up by total curettage every 12 months for 3 years. Progression to carcinoma occurred in only one of the 77 patients; she showed grade 1 adenocarcinoma. The overall regression rates were 79% for SH, 100% for SHA, 94% for CH, and 55% for CHA, respectively. In patients with CHA whose disease reverted to normal endometrium, regression was most likely to occur within the first year.

Entities:  

Mesh:

Year:  2001        PMID: 11409481     DOI: 10.1007/s004040000151

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  7 in total

1.  The effectiveness of levonorgestrel releasing intrauterine system in the treatment of endometrial hyperplasia in Korean women.

Authors:  Seo Yeong Lee; Mi Kyoung Kim; Hyun Park; Bo Sung Yoon; Seok Ju Seong; Jin Hee Kang; Hye Sun Jun; Chong Taik Park
Journal:  J Gynecol Oncol       Date:  2010-06-30       Impact factor: 4.401

Review 2.  Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases.

Authors:  Mi-La Kim; Seok Ju Seong
Journal:  Obstet Gynecol Sci       Date:  2013-03-12

3.  Biological behavior of preneoplastic conditions of the endometrium: A retrospective 16-year study in south India.

Authors:  Shalinee Rao; Sandhya Sundaram; Raghavan Narasimhan
Journal:  Indian J Med Paediatr Oncol       Date:  2009-10

4.  Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia.

Authors:  James V Lacey; Mark E Sherman; Brenda B Rush; Brigitte M Ronnett; Olga B Ioffe; Máire A Duggan; Andrew G Glass; Douglas A Richesson; Nilanjan Chatterjee; Bryan Langholz
Journal:  J Clin Oncol       Date:  2010-01-11       Impact factor: 44.544

5.  Concurrent and future risk of endometrial cancer in women with endometrial hyperplasia: A systematic review and meta-analysis.

Authors:  Michelle T Doherty; Omolara B Sanni; Helen G Coleman; Chris R Cardwell; W Glenn McCluggage; Declan Quinn; James Wylie; Úna C McMenamin
Journal:  PLoS One       Date:  2020-04-28       Impact factor: 3.240

6.  Risk of atypical hyperplasia and endometrial carcinoma after initial diagnosis of non-atypical endometrial hyperplasia: A long-term follow-up study.

Authors:  Clara M Prip; Maria Stentebjerg; Mary H Bennetsen; Lone K Petersen; Pinar Bor
Journal:  PLoS One       Date:  2022-04-12       Impact factor: 3.240

7.  Endometrial carcinoma risk among women diagnosed with endometrial hyperplasia: the 34-year experience in a large health plan.

Authors:  J V Lacey; O B Ioffe; B M Ronnett; B B Rush; D A Richesson; N Chatterjee; B Langholz; A G Glass; M E Sherman
Journal:  Br J Cancer       Date:  2007-11-20       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.